VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Dateline City:
CHICAGO
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the investigational IMPROVE-IT study met its
primary and all secondary composite efficacy endpoints.
Language:
English
Contact:
MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185
Ticker Slug:
...
Source: Merck.com - Product News - November 17, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Surprise! Vytorin Works. Here Are Five Things You Should Know.
For 12 years, there’s been a raging, multibillion-dollar controversy in the giant market for cholesterol-lowering drugs taken by 20 million or more Americans: do one set of pills, Zetia and Vytorin from Merck, actually prevent heart attacks or are the pills, in the memorable words of one top cardiologist, expensive placebos? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
CardioBreak: Energy Drinks, Gene Clues on Ezetimibe
(MedPage Today) -- Recent developments of interest in cardiovascular medicine. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe
After all the waiting and all the controversy it turned out to be pretty simple. The IMPROVE-IT trial did what it set out to do and reached its primary endpoint. The benefit wasn't very big or impressive but it will be enough to put to rest concerns that ezetimibe might have been an expensive placebo or that LDL might not be a reliable surrogate endpoint. The IMPROVE-IT results will also provide comfort to companies developing the next generation of cholesterol drugs, since their approval may have depended on validation of LDL as a surrogate endpoint. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
AHA: IMPROVE-IT Proves Ezetimibe Benefit (CME/CE)
(MedPage Today) -- Statins are good at reducing cholesterol, but a statin plus ezetimibe is even better. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
Merck & Co says long-term cholesterol drug study met primary endpoint
Merck said that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2014 Category: Pharmaceuticals Source Type: news
Merck says long-term cholesterol drug study met primary endpoint
(Reuters) - Merck & Co said on Monday that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol, had met its primary endpoint. (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
After Years Under Attack, Merck's Vytorin Proves Effective
Since 2007, the blockbuster cholesterol pills Zetia and Vytorin have been under a cloud as many doctors questioned their effectiveness at preventing heart attacks – and those questions have caused prescriptions of the pills to fall by more than 50%. Today, that cloud lifts. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Researchers present highly anticipated IMPROVE-IT results
(Brigham and Women's Hospital) Results of the highly anticipated IMProved Reduction of Outcomes: Vytorin Efficacy International Trial, also known as IMPROVE-IT, co-led by researchers at Brigham and Women's Hospital and Duke Medicine, indicate that adding a second drug, ezetimibe, that blocks cholesterol absorption, resulted in a significant 6.4 percent reduction in the number of cardiovascular events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2014 Category: Global & Universal Source Type: news
Researchers Present Highly Anticipated IMPROVE-IT Results
Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack (Source: BWH News)
Source: BWH News - November 17, 2014 Category: Hospital Management Source Type: news
'Inactivating' NPC1L1 Mutations Protect Against CHD'Inactivating' NPC1L1 Mutations Protect Against CHD
Mutations in a gene for the same protein targeted by ezetimibe may protect against CHD, a finding that comes less than a week before the world learns how ezetimibe performed in the IMPROVE-IT study. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
U.S. gene study raises hope for Merck cholesterol drug Zetia
CHICAGO (Reuters) - Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia. (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Future of Merck cholesterol sales could hang on long-awaited study
(Reuters) - A nine-year, 18,000-patient study of Merck & Co's $4 billion Zetia and Vytorin cholesterol franchise is likely to show some benefit but keep open the question of whether it can significantly reduce heart attacks, strokes and death. (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Merck expects no writedowns for Zetia, Vytorin cholesterol drugs
(Reuters) - Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
